<HashMap><database>biostudies-arrayexpress</database><scores/><additional><omics_type>Unknown</omics_type><omics_type>Transcriptomics</omics_type><omics_type>Genomics</omics_type><omics_type>Proteomics</omics_type><submitter>John Thomson</submitter><study_type>methylation profiling by array</study_type><organism>Mus musculus</organism><species>Mus musculus</species><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/E-GEOD-41392</full_dataset_link><description>5-hmC is an epigenetic modification of the DNA base cytosine with roles in gene silencing events, imprinting and X inactivation. Phenobarbital (PB) is a well studied non-genotoxic carcinogen with roles in epigenetic perturbation.  We profile 5hmC in both control mouse livers as well as in the livers of 7 day PB treated mice. 5hmC is largely found to reside in the bodies of active genes and promoter levels are perturbed upon PB induced gene activation events. 5-hmC is assocated with promoters fo silent genes. Upon PB exposire a handfull of genes are induced which reveal decreases in promoter 5hmC levels comparison of 5-hmC profiles in 5 control and 5 PB exposed mouse livers (dose: 7day PB)</description><repository>biostudies-arrayexpress</repository><sample_protocol>Growth Protocol - normal mouse liver tissue</sample_protocol><sample_protocol>Sample Processing - genomic DNA extracted from mouse liver following 7 day exposed to Phenobarbital</sample_protocol><sample_protocol>Nucleic Acid Extraction - Genomic DNA (5hmC-IP - 2.5 M-5g in 450 M-5l TE), sonicated to yield a fragment distribution of approximately 300-1000 bp, was denatured by incubation at 100M-0C for 10 min. Samples were rapidly chilled on wet-ice. At this point, 45 M-5l (10%) of denatured sample was removed and saved as input, and 45 M-5l of 10X IP buffer (100 mM Na-Phosphate pH 7.0 (mono and dibasic), 1.4 M NaCl, 0.5 % Triton X-100) and 1 M-5g of M-oM-^AM-!-5hmC (ActiveMotif; #39769) antibody were added to the remaining sample. Samples were incubated at 4M-oM-^BM-0C with gentle agitation overnight. Then, 40 M-5l of magnetic beads (DynabeadsM-. Protein G, Invitrogen, UK) in 1X IP buffer were added to each sample to allow magnetic separation of the antibody from the unbound DNA using a magnetic tube rack. Samples were incubated at 4M-oM-^BM-0C for 1 hr with gentle agitation. Beads were collected with a magnetic rack and washed with 1000 M-5l of 1X IP buffer at RT for 10 min with gentle agitation; washing was repeated three times. Beads were collected with a magnetic rack and re-suspended in 250 M-5l of digestion buffer (50 mM Tris pH 8.0, 10 mM EDTA , 0.5 % SDS) followed by addition of 10 M-5l of proteinase K (20 mg/ml; Roche Applied Science, Mannheim, Germany) and incubation at 52M-oM-^BM-0C for 1.5 hr with constant shaking (M-bM-^IM-%800 rpm). Finally, beads were removed using a magnetic rack and DNA was purified from the remaining sample using a QIAquickM-oM-^CM-^R PCR Purification Kit (QIAGEN,CA, USA), eluting in a final volume of 40 M-5l dH2O. Inputs were also purified using a QIAquickM-oM-^CM-^R PCR Purification Kit and eluted in 40 M-5l dH2O. Subsequently, 10 ng of input and IP DNA was subjected to whole genome amplification (WGA) using the GenomePlexM-. Complete Whole Genome Amplification Kit (Sigma-Aldrich, UK) as per the manufacturer's instructions. Amplified DNA was run on a 1.2% agarose gel to confirm consistency of fragment size between samples.</sample_protocol><sample_protocol>Growth Protocol - PB exposed mouse liver tissue</sample_protocol><sample_protocol>Labeling - Amplification of DNA samples was carried out commercially by NimbleGen, Iceland (Cy5- (IP) or Cy3- (Input) labelled)</sample_protocol><sample_protocol>Hybridization - Labelled samples were applied commercially to a Nimblegen 2.1M Deluxe promoter array by Nimblegen, Iceland</sample_protocol><sample_protocol>Sample Processing - genomic DNA extracted from normal mouse liver</sample_protocol><figure_sub>MIAME Score</figure_sub><figure_sub>Raw Data</figure_sub><figure_sub>Organization</figure_sub><figure_sub>Assays and Data</figure_sub><figure_sub>Processed Data</figure_sub><figure_sub>MAGE-TAB Files</figure_sub><figure_sub>Array Designs</figure_sub><pubmed_authors>Harri LempiM-CM-$inen</pubmed_authors><pubmed_authors>John Thomson</pubmed_authors><data_protocol>Feature Extraction - Pair files normalised within arrays (loess), normalised between arrays (sclae normalisation), log2(IP/input)</data_protocol><data_protocol>Assay Data Transformation - ID_REF =  VALUE = Normalised data after normalised within arrays (loess) and between arrays (scale normalisation) resulting in log2(IP/input) scores for each probe</data_protocol><data_protocol>Image Adquisition - Arrays were scanned commercially by Nimblegen, Iceland</data_protocol></additional><is_claimable>false</is_claimable><name>IP of 5-methylcytosine (5-hmC) enriched DNA fragments from control and PB treated mouse livers (7 day)</name><description>5-hmC is an epigenetic modification of the DNA base cytosine with roles in gene silencing events, imprinting and X inactivation. Phenobarbital (PB) is a well studied non-genotoxic carcinogen with roles in epigenetic perturbation.  We profile 5hmC in both control mouse livers as well as in the livers of 7 day PB treated mice. 5hmC is largely found to reside in the bodies of active genes and promoter levels are perturbed upon PB induced gene activation events. 5-hmC is assocated with promoters fo silent genes. Upon PB exposire a handfull of genes are induced which reveal decreases in promoter 5hmC levels comparison of 5-hmC profiles in 5 control and 5 PB exposed mouse livers (dose: 7day PB)</description><dates><release>2012-11-10T00:00:00Z</release><modification>2023-08-29T13:27:54.104Z</modification><creation>2021-10-08T11:17:32Z</creation></dates><accession>E-GEOD-41392</accession><cross_references><GEO>GSE41392</GEO><EFO>EFO_0002759</EFO></cross_references></HashMap>